eXoZymes AI Stock Analysis
Want to see EXOZ full AI Analyst Report?
eXoZymes (EXOZ) AI Stock Analysis
eXoZymes
(NASDAQ:EXOZ)
The overall score of 39 is heavily weighed down by EXOZ's highly speculative pre-revenue status, severe cash burn, and a depleting equity base that urgently requires external financing. These fundamental vulnerabilities are further compounded by a stark technical downtrend and poor valuation metrics. While recent corporate outreach efforts demonstrate an active attempt to secure much-needed capital, the immediate financial instability and market risks remain the dominant factors driving this low score.
eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $37.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 9,579
- Price to Earnings (P/E)
- -3.2
- Beta (1Y)
- 1.20
- Revenue Growth
- ―
- EPS Growth
- -17.50%
- Country
- US
- Employees
- 32
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
eXoZymes Business Overview & Revenue Model
Company Description
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc...
How the Company Makes Money
null
eXoZymes Financial Statement Overview
Summary
Scored at the lowest threshold due to zero revenue, widening net losses, and a severe cash burn rate reaching $7.36 million in the trailing twelve months, signaling critical near-term liquidity risks.
Income Statement
15Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 55.26K | 0 | -267.38K | 0 | -147.75K | -59.41K |
| EBITDA | -11.25M | -8.98M | -5.59M | -1.80M | -1.18M | -1.15M |
| Net Income | -10.14M | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
Balance Sheet | ||||||
| Total Assets | 5.86M | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.26M | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Total Debt | 1.00M | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Total Liabilities | 3.67M | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Stockholders Equity | 2.19M | 3.40M | 10.42M | -384.32K | 1.37M | 1.20M |
Cash Flow | ||||||
| Free Cash Flow | -7.80M | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
| Operating Cash Flow | -7.36M | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Investing Cash Flow | -297.36K | -150.22K | -359.22K | -311.17K | -87.21K | -312.25K |
| Financing Cash Flow | 5.82M | -27.71K | 18.52M | 1.00M | 1.36M | 2.31M |
eXoZymes Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXOZ, the sentiment is Negative. The current price of 3.99 is below the 20-day moving average (MA) of 4.11, below the 50-day MA of 5.06, and below the 200-day MA of 7.39, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 41.08 is Neutral, neither overbought nor oversold. The STOCH value of 23.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EXOZ.
eXoZymes Risk Analysis
eXoZymes disclosed 47 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RiskseXoZymes Peers Comparison
Overall Rating
NCEL48Neutral
BDRX40Underperform
EXOZ39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 48Neutral | $14.81M | 8.32 | 21.75% | ― | ― | ― | |
| 40Underperform | $1.17M | -44.55 | -42.42% | ― | ― | 97.97% | |
| 39Underperform | $37.67M | -3.24 | -376.66% | ― | ― | -17.50% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EXOZ | Exozymes Inc. | 3.99 | -10.53 | -72.52% | |
| BDRX | Biodexa Pharmaceuticals Plc | 2.24 | -181.76 | -98.78% | |
| ADTX | Aditxt, Inc. | 0.04 | -881.24 | -100.00% | |
| NCEL | Newcelx Ltd. | 2.75 | -0.65 | -19.12% | |
| VRAX | Virax Biolabs Group Ltd. Class A | 0.45 | -10.82 | -96.02% |
eXoZymes Corporate Events
eXoZymes Highlights Investor Presentation for Capital Markets Outreach
PositiveOn October 6, 2026, eXoZymes Inc. prepared an investor presentation intended for distribution to investment bankers, offering participants, and existing and prospective investors. The document, filed as an exhibit, is designed to support the company’...
eXoZymes Sets Date for 2026 Shareholders Meeting
NeutraleXoZymes announced that it scheduled its 2026 annual meeting of shareholders for November 13, 2026, setting a formal timeline for its upcoming governance and voting activities. The company established September 15, 2026 as the record date to determin...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
